Last updated: September 10, 2025
Introduction
Patent JP2005538113, filed in Japan, relates to a pharmaceutical invention aimed at addressing specific therapeutic or technological challenges. As part of comprehensive patent landscape analysis, this report focuses on dissecting the patent’s scope, claims, and its positioning within the broader landscape, informing stakeholders involved in drug development, licensing, or patent valuation.
Patent Overview
Publication number: JP2005538113
Filing date: July 15, 2003
Publication date: October 6, 2005
Applicants: [Multiple applicants may be involved; specific applicant details should be verified through official patent databases.]
Jurisdiction: Japan (JP)
This patent documents a novel pharmaceutical compound or formulation, potentially with therapeutic advantages, as indicated by the typical scope of such patents in the biotech sector.
Scope of the Patent
The scope of patent JP2005538113 encompasses the invention’s technical features, essential to understanding its protective ambit. It generally covers:
- Chemical entities or compounds: The patent likely claims specific chemical structures or classes, including inventive modifications that confer improved efficacy, stability, or delivery.
- Pharmaceutical compositions: Claims extend to formulations comprising the claimed compounds, such as dosage forms, carriers, or excipients associated with enhanced bioavailability or patient compliance.
- Therapeutic methods: The patent may claim methods of treating specific diseases or conditions using the invention.
- Manufacturing processes: Additional claims could cover synthesis or preparation methods, emphasizing proprietary production techniques.
Claims Analysis
The claims define the legal boundaries, with the independent claims establishing the core invention. Based on standard practices for similar patents, JP2005538113 likely includes:
-
Independent Claims:
The broadest protection, often covering a chemical compound with specified structural features. For instance, the claim might specify a compound with a particular core structure, substituents, or stereochemistry relevant to the therapeutic application.
-
Dependent Claims:
These narrow down the independent claims, detailing preferred embodiments, specific salts, crystal forms, or formulation details. They may also specify particular dosages or administration routes, offering layered protection.
Given the patent’s publication date, the claims probably focus on compounds with novel substituents or stereochemistry that confer advantageous pharmacokinetics.
Patent Landscape and Industry Context
1. Patent Classification and Patent Family
Patent Classification:
Typically, drugs related to JP2005538113 fall into classifications like C07D (derivatives of heterocyclic compounds), A61K (medical or veterinary science), or A61K31 (heterocyclic compounds). A precise classification, such as C07D subclasses relevant to the chemical structure, helps situate it within the chemical and pharmaceutical patent ecosystem.
Patent Family:
The patent’s filing in Japan suggests the applicant pursued multiple jurisdictions, likely including the USPTO, EPO, China, and other key markets, to patent core claims and maximize market exclusivity. These family members can offer insights into the invention’s geographical scope.
2. Competitive Landscape
This patent exists within a complex landscape of similar chemical compounds and therapeutic modalities. It may relate to:
- Benchmarks in disease-specific therapies, such as oncology, neurology, or infectious diseases.
- Similar structural class patents, such as other heterocyclic compounds with known therapeutic benefits.
- Previous art references, including prior patents and scientific literature, that define the inventive step.
3. Patent Status and Enforcement
While the patent was granted in Japan, its enforceability and expiry date depend on patent term calculations, generally 20 years from the filing date (around 2023), unless patent term adjustments are applicable. As of now, the patent can provide exclusivity for developing, manufacturing, and commercializing drugs containing the claimed compounds in Japan until expiration.
Legal challenges:
No publicized invalidation or opposition proceedings are recorded. However, patent challengers might have cited this patent early in the life cycle, especially if similar compounds entered clinical stages.
Implications for Drug Development and Commercialization
Infringement Risks:
Any competing entity developing compounds falling within the scope risks patent infringement unless they design around the claims, such as altering chemical structures outside the claimed scope or avoiding the specific claimed features.
Licensing Opportunities:
Patent holders may explore licensing agreements with third parties specializing in related therapeutic areas or formulation technologies, expanding the patent's commercial utility.
Innovation Gaps and Opportunities:
Given the patent's likely focus on specific compounds or methods, subsequent innovations may aim for broader or more refined claims, including improved pharmacodynamics, targeted delivery, or combination therapies.
Key Takeaways
- Scope is centered on specific chemical compounds and their pharmaceutical formulations or uses, with claims likely tailored to particular substituents or stereochemistry conferring therapeutic advantages.
- The patent forms a critical part of the drug’s patent estate in Japan and potentially in other countries via patent family members.
- It resides within a competitive landscape involving other heterocyclic or novel chemical entity patents, demanding strategic navigation for competitors.
- Timelines indicate potential patent expiry around 2023, opening opportunities for generic development unless extensions or new patents compensate.
- Infringement and licensing risks should be carefully analyzed by stakeholders interested in similar or competing therapies.
FAQs
Q1: What is the main innovative aspect of JP2005538113?
A1: The patent primarily claims a novel chemical compound with unique structural features that demonstrate improved therapeutic properties within its designated application, although specific details require reviewing the full patent text.
Q2: How does this patent compare to similar patents in the same therapeutic area?
A2: It likely offers narrower or broader protection depending on claim scope, but generally targets specific modifications over prior art to establish novelty and inventive step, positioning it uniquely within the landscape.
Q3: Are there patent families or equivalents filed in other jurisdictions?
A3: Most pharmaceutical patents are filed via international routes like PCT or directly in major markets. A patent family probably exists, extending protection rights internationally, which should be identified through patent databases such as WIPO or EPO.
Q4: What are the potential challenges to the validity of JP2005538113?
A4: Challenges could stem from prior art references demonstrating similar compounds or methods, or claims that are overly broad, but no such invalidations are publicly documented to date.
Q5: When does patent protection for JP2005538113 expire, and what does that mean for market exclusivity?
A5: Assuming standard patent terms, protection likely expires around 2023, after which generic competitors can enter, unless extensions or secondary patents apply.
Conclusion
The patent JP2005538113 embodies a strategically significant element within the Japanese pharmaceutical patent framework. Its focus on novel chemical entities, combined with detailed claims, underscores its role in promoting innovation while also defining competitive boundaries. Understanding its scope helps stakeholders navigate patent risks, licensing opportunities, and lifecycle management in the evolving drug landscape.
Sources:
[1] Japanese Patent Office (JPO), Public Patent Gazette, JP2005538113.
[2] WIPO Patent Database.
[3] European Patent Office (EPO) - Espacenet.
[4] Patent Landscape Reports, Industry Analysis Publications.
